The inhibition of mouse ERK1/2 activation in AKI using the mitogen-activated protein kinase 1/2 (MEK1/2) inhibitor trametinib attenuated renal cortical NAD+ depletion. This evidence concerns the gene MAP2K1 and acute kidney injury.